To evaluate the benefits and harms of tofacitinib for the treatment of rheumatoid arthritis.

Our PICO question is as follows:

Population: Adult patients with rheumatoid arthritis.

Intervention: Tofacitinib alone or combined with any DMARD.

Comparison: Placebo or DMARD.

Outcomes: Efficacy, radiographic, patient-reported and safety outcomes.